As Europe’s cannabis industry edges closer to a transformative new era, the spotlight is increasingly falling on the clinical application of medicinal cannabis. With evolving regulations, rising demand for evidence-based treatments, and a renewed focus on patient outcomes, clinical settings are at the heart of the cannabis conversation in 2025.

Cannabis Europa has become a pivotal platform for shaping the future of Europe’s cannabis sector – bringing together policymakers, healthcare professionals, and business leaders to discuss the region’s unique and responsible path toward cannabis regulation and innovation.

One of the key topics expected to dominate the discussion is how medicinal cannabis is being integrated into clinical care – from pain management and palliative treatment to its growing use in managing conditions such as epilepsy, multiple sclerosis, and chemotherapy-induced side effects. This growing clinical adoption demands not only scientific rigour and clinical excellence but also a robust understanding of the regulatory environment.

At WBR, we specialise in supporting life science and healthcare innovators to successfully navigate this complex and highly regulated space. Whether you’re developing cannabinoid-based therapies or looking to enter the UK or European market, we can help you manage every step of the regulatory journey – from product classification and dossier preparation, to engagement with regulatory bodies and eventual route to registration.

How WBR Can Support You in the Medicinal Cannabis Space:

  • GMP / GDP Certification: with extensive experience with the development and implementation of Quality Systems, we’ve successfully completed MHRA GDP certification for a number of clients in the UK and EU.
  • Regulatory Pathway Guidance: Understanding whether your product is classified as a medicinal product, medical device, or food supplement is essential. We help businesses determine the correct regulatory pathway based on intended use, formulation, and target markets.
  • Clinical Development Support: From trial design to ethics submissions, we can support your clinical programme to ensure it meets local and international standards, particularly where medicinal cannabis is involved.
  • Dossier and Documentation Preparation: We have extensive experience in compiling and submitting regulatory documentation in line with MHRA, EMA, and other agency requirements.
  • Market Access Strategy: Regulatory compliance is only one part of the picture. We work with you to build a roadmap that takes your product from development to launch, considering pricing, reimbursement, and real-world evidence strategies along the way.
  • Regulatory Intelligence and Updates: The medicinal cannabis space is rapidly evolving, with shifting requirements across jurisdictions. Our team stays ahead of the curve so you don’t have to – providing tailored intelligence and strategic advice.

As the European cannabis sector matures, and more clinical data emerges to support the therapeutic potential of cannabinoids, it’s vital that companies entering this space do so with confidence, integrity, and clarity.

With Cannabis Europa 2025 around the corner, we’re actively working with clients across the sector to drive innovation, patient access, and regulatory excellence. If you’re looking to bring a medicinal cannabis product to market, or need support understanding how new regulations could affect your business, WBR is here to help.

Contact us to find out how we can support your next steps in the medicinal cannabis space.

Back to News + Insights